| **Eligibility Term**                                                   | **Neurological Disorder Type** | **Category**       | **% of Trials (in category)** | **Inclusion/Exclusion** | **FHIR Resource**   | **Code (LOINC/SNOMED/ICD)** | **Unstructured EMR Example**                                              |
| ---------------------------------------------------------------------- | ------------------------------ | ------------------ | ----------------------------- | ----------------------- | ------------------- | --------------------------- | ------------------------------------------------------------------------- |
| Diagnosis of definite or probable ALS per revised El Escorial criteria | ALS                            | Diagnosis          | 100.0%                        | Inclusion               | Condition           | ICD-10: G12.21              | Patient meets El Escorial criteria for probable ALS.                      |
| Symptom onset within past 2 to 3 years                                 | ALS                            | Clinical           | 87.5%                         | Inclusion               | Observation         | SNOMED: 248536006           | Initial bulbar symptoms began approximately 20 months ago.                |
| Age 18 to 75 years                                                     | ALS                            | Demographic        | 100.0%                        | Inclusion               | Patient             | LOINC: 30525-0              | Patient is 54 years old and meets the age requirement.                    |
| ALS Functional Rating Scale-Revised (ALSFRS-R) score ≥ 30              | ALS                            | Clinical           | 75.0%                         | Inclusion               | Observation         | LOINC: 89262-1              | ALSFRS-R score was 34 at screening.                                       |
| Slow vital capacity (SVC) ≥ 60% predicted                              | ALS                            | Lab                | 75.0%                         | Inclusion               | Observation         | LOINC: 19870-5              | Baseline SVC measured 65% of predicted value.                             |
| Able to swallow oral medication                                        | ALS                            | Clinical           | 62.5%                         | Inclusion               | Observation         | SNOMED: 26643006            | Patient able to swallow tablets without difficulty.                       |
| Use of riluzole permitted if stable dose ≥ 30 days                     | ALS                            | Medication History | 62.5%                         | Inclusion               | MedicationStatement | SNOMED: 428181000124101     | Riluzole continued at 50 mg BID for last 2 months.                        |
| No gastrostomy tube (PEG) for feeding at screening                     | ALS                            | Clinical           | 50.0%                         | Exclusion               | Procedure           | SNOMED: 26643006            | Patient feeds orally and does not use PEG tube.                           |
| No tracheostomy or use of invasive ventilation at baseline             | ALS                            | Clinical           | 62.5%                         | Exclusion               | Procedure           | SNOMED: 426933007           | Patient breathes unassisted and has no tracheostomy.                      |
| Women of childbearing potential must use effective contraception       | ALS                            | Administrative     | 62.5%                         | Inclusion               | Consent             | SNOMED: 225426000           | Subject agreed to use hormonal contraception for duration of study.       |
| Negative pregnancy test before enrollment                              | ALS                            | Lab                | 62.5%                         | Inclusion               | Observation         | LOINC: 2106-3               | Serum pregnancy test was negative at screening.                           |
| Adequate liver and kidney function                                     | ALS                            | Lab                | 75.0%                         | Inclusion               | Observation         | LOINC: 2160-0, 1920-8       | Liver enzymes and serum creatinine within normal limits.                  |
| No participation in another investigational drug trial within 30 days  | ALS                            | Treatment History  | 50.0%                         | Exclusion               | MedicationStatement | SNOMED: 428181000124101     | Not currently or recently enrolled in any other trial.                    |
| No history of other significant neurologic disorders (e.g., MS, PD)    | ALS                            | Diagnosis          | 50.0%                         | Exclusion               | Condition           | ICD-10: G35, G20            | Patient has no known history of Parkinson’s or multiple sclerosis.        |
| Willing and able to comply with all study procedures                   | ALS                            | Administrative     | 87.5%                         | Inclusion               | Patient             | SNOMED: 386053000           | Participant confirmed availability and willingness to attend all visits.  |
| Able to provide informed consent                                       | ALS                            | Administrative     | 100.0%                        | Inclusion               | Consent             | SNOMED: 11341000146104      | Patient gave written informed consent before any study-related procedure. |
